MYX new all time highs, if and when possible?

Looks like bull is holding its fire  after positioning itself above 90.
Waiting for numbers on 24th Aug 18.
Looks like if they are OK as expected
we go through one dollar then if not before.
If all keeps going well,
under that scenario MYX
may hit all time new highs by August 2019 end rather than my previous likely price projection of above 2 dollars by Dec 2019 end.
Here are few points from Feb 2018  presentation.
Have a good read  to refresh yourself as a long term investor.


Some interesting reading from 1H 2018 FINNCL YR report.

23 February 2018 MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE • Revenue of $243.3m, a decrease of 17% on 1HFY17 • Adjusted EBITDA of $70.2m, down 36% on 1HFY17 • Reported EBITDA of $23.0m, down 82% on 1HFY17 • Reported net loss after tax of $174.2m driven by asset impairments, abnormal Doryx® returns and stock obsolescence, restructuring expenses and restatement of deferred tax assets and liabilities following the US tax rate change • Positive operating cash flow of $48.0m • Significantly improved trading in 2QFY18 which has strengthened further into January • US generic market appears to be stabilising and competitor disruptions creating opportunities • Expanded Specialty Brands team to 120 sales representatives to drive growth of Fabior®, Sorilux® and Doryx® MPC • New Greenville manufacturing facility to commence production in the next month, enhancing internal capabilities and improving margins for third party transferred products • Business positioned for a stronger second half driven by stabilising generic market, new product launches, expanded dermatology sales team, contract services committed business pipeline and cost benefits from the restructure.

The pipeline is expected to drive growth in future periods driven by key launches including generic NuvaRing® and our patented formulation of SUBA®- Itraconazole as an anti-fungal in the United States.”

Summary of results1 Change on pcp $m 1HFY18 1HFY17 pcp $m % Revenue 243.3 294.8 (51.5) (17%) Gross profit 95.9 171.2 (75.3) (44%) GM% 39% 58% EBITDA – adjusted2 70.2 109.9 (39.7) (36%) EBITDA – reported 23.0 129.2 (106.2) (82%) Net income / (loss) - adjusted 16.0 59.5 (43.5) (73%) Net income / (loss) - reported (174.2) 72.7 (256.9) Nm

Adjusting for these one-off items, group revenue would have been down 13% on pcp, gross profit margin would have been 50% and adjusted EBITDA was $70.2m down 36%.

(Oh dear. These margins are higher than CSL)
What do you want to say here..

The Company remains committed to growing its core business segments by investing in both internal and external product development opportunities. During the half, the Company invested $63m in its facilities and product pipeline with $40m primarily spent on the expansion programs at Greenville and Salisbury, in addition to $23m on research and development. The solid oral dose manufacturing facility in Greenville is almost complete and the Company is in the process of transferring in house 8 acquired Teva products which are currently outsourced. This will increase the economic benefit that flows to Mayne Pharma as well as introduce downstream commercial manufacturing services to Metrics Contract Services